RiceBran Technologies - RIBT Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RiceBran Technologies in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RIBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIBT, but not buy additional shares or sell existing shares.
View RIBT analyst ratings or view top-rated stocks.

RiceBran Technologies' stock was trading at $0.3490 at the beginning of the year. Since then, RIBT shares have decreased by 3.0% and is now trading at $0.3385.
View the best growth stocks for 2022 here.

RiceBran Technologies saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 641,400 shares, a drop of 45.6% from the July 15th total of 1,180,000 shares. Based on an average daily volume of 4,140,000 shares, the days-to-cover ratio is presently 0.2 days.
View RiceBran Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our RIBT earnings forecast.

RiceBran Technologies will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "46275".

RiceBran Technologies (NASDAQ:RIBT) posted its earnings results on Wednesday, October, 27th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $6.91 million for the quarter. RiceBran Technologies had a negative trailing twelve-month return on equity of 36.82% and a negative net margin of 33.42%.

Based on aggregate information from My MarketBeat watchlists, some companies that other RiceBran Technologies investors own include OPKO Health (OPK), vTv Therapeutics (VTVT), Pareteum (TEUM), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Palatin Technologies (PTN), Trevena (TRVN), VBI Vaccines (VBIV), VistaGen Therapeutics (VTGN) and Alimera Sciences (ALIM).

RiceBran Technologies trades on the NASDAQ under the ticker symbol "RIBT."

RiceBran Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Arnhold LLC (0.39%) and FNY Investment Advisers LLC (0.20%). Insiders that own company stock include Ari David Gendason, Baruch Halpern, Brent David Rosenthal, Brent Robert Rystrom, David I Chemerow, Grain Co Continental and Todd T Mitchell.
View institutional ownership trends.

Shares of RIBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RIBT stock can currently be purchased for approximately $0.34.

RiceBran Technologies (NASDAQ:RIBT) has a market capitalization of $17.71 million and generates $31.13 million in revenue each year. The company earns $-8,950,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 101 workers across the globe.

RiceBran Technologies' mailing address is 1330 LAKE ROBBINS DRIVE SUITE 250, THE WOODLANDS TX, 77380. The official website for the company is www.ricebrantech.com. The company can be reached via phone at (281) 675-2421, via email at rich@ascendantpartnersllc.com, or via fax at 602-522-3001.